Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With a BRAF V600E Mutation Low-Grade Glioma in England and Wales.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Aug 2026

Rafia Rachid, Ibrahim Munna, Kane Nicole, Hargrave Darren, Marshall Lynley Vanessa, Jameson Kevin

Abstract excerpt

OBJECTIVES: Pediatric low-grade gliomas are rare diseases, but they remain the most common pediatric brain tumor and pose a significant burden to children, adolescents, and their families. The combination (D+T) of dabrafenib and trametinib was assessed in the TADPOLE trial in pediatric patients with glioma with a BRAF V600E mutation. The aim of this analysis is to assess the cost-effectiveness of D+T compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Costs
Share to England

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Economic

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 41825798
DOI: 10.1016/j.jval.2026.02.017

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With a BRAF V600E Mutation Low-Grade Glioma in England and Wales.PMID 41825798Read ↗

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.Semantic proximity Read ↗

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read ↗

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.Semantic proximity Read ↗

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.Semantic proximity Read ↗

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.Semantic proximity Read ↗

Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudySemantic proximity Read ↗

Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.Semantic proximity Read ↗

Targeted Therapy Win in BRAF-Mutant Gliomas.Semantic proximity Read ↗

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read ↗

Dabrafenib-trametinib is effective in paediatric high-grade glioma.Semantic proximity Read ↗

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.Semantic proximity Read ↗

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.